Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB763 (Nidufexor) in Patients With NASH
NCT02913105Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing LMB763 with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at Day 112 and Change From Baseline in Alanine Aminotransferase Levels at Week 12. Started Oct 2016; status: terminated.
02
Drugs
nidufexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02913105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913105.